Knowledge Translation in OncologyThe Bumpy Ride From Bench to Bedside

被引:7
|
作者
Morgan, Sarah [1 ,2 ]
Hanna, Jessica [1 ,2 ]
Yousef, George M. [1 ,2 ]
机构
[1] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[2] Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON, Canada
关键词
Knowledge translation; Precision medicine; Molecular pathology; Personalized medicine; PRIMARY-CARE; GENOMIC MEDICINE; DECISION-SUPPORT; GENETIC SERVICES; RISK-ASSESSMENT; CANCER; INTEGRATION; PHYSICIANS;
D O I
10.1093/ajcp/aqz099
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Knowledge translation (KT) is the dynamic process of mobilizing best-practice evidence to guide health care decisions. Methods: Using a PubMed search, challenges were identified and milestones defined. Results: Substantial challenges exist in integrating discoveries into patient care, including technical limitations related to genomic testing like turnaround time, standardization, reproducibility, and results interpretation. Other challenges include lack of proper training in genetic counseling for health care providers, clarity of scientific evidence, and ethical, legal and social considerations. In addition, most health care systems lack accessibility to genetic testing services. Moving forward, KT should be addressed at three main frontiers. The first is patients centered for proper understanding and decision making; the second is directed toward health care professionals, including clinical decision support and clarity of roles; and the third addresses resources of health care systems. Conclusions: Implementing KT requires developing strategies to enhance awareness and promote behavioral changes congruent with research evidence, designing a systematic approach by health care providers and stakeholders to achieve patient-centered care.
引用
收藏
页码:5 / 13
页数:9
相关论文
共 50 条
  • [31] Technological Advances in Tumor-On-Chip Technology: From Bench to Bedside
    Berzina, Santa
    Harrison, Alexandra
    Taly, Valerie
    Xiao, Wenjin
    CANCERS, 2021, 13 (16)
  • [32] Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
    Katsetos, Christos D.
    Draber, Pavel
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (19) : 2778 - 2792
  • [33] Cancer photo-immunotherapy: from bench to bedside
    Wang, Miao
    Rao, Jie
    Wang, Meng
    Li, Xiaosong
    Liu, Kaili
    Naylor, Mark F.
    Nordquist, Robert E.
    Chen, Wei R.
    Zhou, Feifan
    THERANOSTICS, 2021, 11 (05): : 2218 - 2231
  • [34] Mitochondrial DNA mutations in cancer - from bench to bedside
    Czarnecka, Anna Malgorzata
    Kukwa, Wojciech
    Krawczyk, Tomasz
    Scinska, Anna
    Kukwa, Andrzej
    Cappello, Francesco
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2010, 15 : 437 - 460
  • [35] Neuroimaging and Psychiatry: The Long Road from Bench to Bedside
    Mayberg, Helen S.
    HASTINGS CENTER REPORT, 2014, 44 : S31 - S36
  • [36] Obstetrics and Gynecology Medicine: Go from Bench to Bedside
    Canosa, Stefano
    Nuzzo, Anna Maria
    LIFE-BASEL, 2025, 15 (02):
  • [37] Delving into PARP inhibition from bench to bedside and back
    Grignani, Giovanni
    Merlini, Alessandra
    Sangiolo, Dario
    D'Ambrosio, Lorenzo
    Pignochino, Ymera
    PHARMACOLOGY & THERAPEUTICS, 2020, 206
  • [38] Editorial: New insights in sarcoidosis: from bench to bedside
    Cameli, Paolo
    Biondini, Davide
    Carleo, Alfonso
    Stock, Carmel J. W.
    FRONTIERS IN MEDICINE, 2023, 10
  • [39] MicroRNA involvement in brain tumors: From bench to bedside
    Nicoloso, Milena S.
    Calin, George A.
    BRAIN PATHOLOGY, 2008, 18 (01) : 122 - 129
  • [40] Editorial: New insights into spondyloarthritis: from bench to bedside
    Lopalco, Giuseppe
    Venerito, Vincenzo
    Ayan, Gizem
    Luchetti, Michele Maria
    Chimenti, Maria Sole
    FRONTIERS IN IMMUNOLOGY, 2024, 15